A prospective study of plasma adiponectin and pancreatic cancer risk in five US cohorts

Ying Bao, Edward L. Giovannucci, Peter Kraft, Meir J. Stampfer, Shuji Ogino, Jing Ma, Julie E. Buring, Howard D. Sesso, I. Min Lee, John Michael Gaziano, Nader Rifai, Michael N. Pollak, Barbara B. Cochrane, Virginia Kaklamani, Jennifer H. Lin, Joann E. Manson, Charles S. Fuchs, Brian M. Wolpin

Research output: Contribution to journalArticlepeer-review

68 Scopus citations

Abstract

Background The adipocyte-secreted hormone adiponectin has insulin-sensitizing and anti-inflammatory properties. Although development of pancreatic cancer is associated with states of insulin resistance and chronic inflammation, the mechanistic basis of the associations is poorly understood. Methods To determine whether prediagnostic plasma levels of adiponectin are associated with risk of pancreatic cancer, we conducted a nested case-control study of 468 pancreatic cancer case subjects and 1080 matched control subjects from five prospective US cohorts: Health Professionals Follow-up Study, Nurses' Health Study, Physicians' Health Study, Women's Health Initiative, and Women's Health Study. Control subjects were matched to case subjects by prospective cohort, year of birth, smoking status, fasting status, and month of blood draw. All samples for plasma adiponectin were handled identically in a single batch. Odds ratios were calculated with conditional logistic regression, and linearity of the association between adiponectin and pancreatic cancer was modeled with restricted cubic spline regression. All statistical tests were two-sided. Results Median plasma adiponectin was lower in case subjects versus control subjects (6.2 vs 6.8 μg/mL, P =. 009). Plasma adiponectin was inversely associated with pancreatic cancer risk, which was consistent across the five prospective cohorts (Pheterogeneity =. 49) and independent of other markers of insulin resistance (eg, diabetes, body mass index, physical activity, plasma C-peptide). Compared with the lowest quintile of adiponectin, individuals in quintiles 2 to 5 had multivariable odds ratios ([ORs] 95% confidence intervals [CIs]) of OR = 0.61 (95% CI = 0.43 to 0.86), OR = 0.58 (95% CI = 0.41 to 0.84), OR = 0.59 (95% CI = 0.40 to 0.87), and OR = 0.66 (95% CI = 0.44 to 0.97), respectively (Ptrend =. 04). Restricted cubic spline regression confirmed a nonlinear association (Pnonlinearity <. 01). The association was not modified by sex, smoking, body mass index, physical activity, or C-peptide (all Pinteraction >. 10). Conclusions In this pooled analysis, low prediagnostic levels of circulating adiponectin were associated with an elevated risk of pancreatic cancer.

Original languageEnglish (US)
Pages (from-to)95-103
Number of pages9
JournalJournal of the National Cancer Institute
Volume105
Issue number2
DOIs
StatePublished - Jan 16 2013
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'A prospective study of plasma adiponectin and pancreatic cancer risk in five US cohorts'. Together they form a unique fingerprint.

Cite this